[Virus Research] Researchers investigated how type I interferon signaling influences the cellular inflammatory response and immunopathology in the central nervous system during ZIKV infection.
[Advanced Science] Scientists identified viral ORF9b as a conserved accessory protein across the Sarbecovirus subgenus that consistently suppresses innate immune responses by recruiting the protein phosphatase, Mg2+/Mn2+-dependent 1A (PPM1A).
[Msphere] To investigate how allergic airway inflammation affects SARS-CoV-2-induced pneumonia, researchers used an ovalbumin-induced airway allergy mouse model and infected mice with QHmusX, a mouse-passaged SARS-CoV-2 strain that causes severe acute pneumonia.
[UC San Diego Today] Dr. Liangfang Zhang has defined his career by creating cell-mimicking nanoparticles to treat disease. For creating this technology, and pioneering its development toward potential treatment infectious diseases and inflammatory disorders, Dr. Zhang has been named a 2026 MacArthur Fellow from the John D. and Catherine T. MacArthur Foundation.
[Cell Systems] The authors established a reference map of cell identity and lineage differentiation of the human blastocysts through the integration and curation of single-cell transcriptome data of ex vivo blastocysts profiled at a range of developmental time points in culture.
[Advanced Science] Through compound library screening, researchers identified Danofloxacin, a small molecule, as a promoter of mESC stemness. Danofloxacin enhances the formation of undifferentiated colonies and the generation of chimeric mice.
[iScience] Researchers reported an unexpected role of PEX19, a chaperone and receptor for peroxisomal membrane proteins, in regulating cell cycle and cell fates of mESCs through a peroxisome-independent mechanism.
[Stem Cell Reports] Scientists showed that the chromatin state of the starting population constrains the neuronal identities that ASCL1 and DLX2 can specify: patterned progenitors give rise to GABAergic neurons with cortical and ganglionic eminence-associated molecular signatures, whereas naive PSCs yield neurons with mixed regional identities, including hypothalamic and thalamic signatures.
[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has awarded the Company a $15.0 million grant, through its CLIN2 program, to support the clinical development of RECLAIM-LN, the Company's Phase II, potentially registrational trial of FT819 off-the-shelf CAR T cell in patients with refractory moderate-to-severe Systemic Lupus Erythematosus (SLE) with Lupus Nephritis (LN).